| 283 | 7 | 158 |
| 下载次数 | 被引频次 | 阅读次数 |
目的：探讨不同剂量普瑞巴林治疗老年带状疱疹(HZ)患者急性期疼痛的临床疗效。方法：选取2021年1月—2022年12月就诊于宜昌市中心人民医院的老年HZ急性疼痛期患者(n=90),根据普瑞巴林剂量随机分为三组，其中150 mg/d为低剂量组(n=30)、300 mg/d为中剂量组(n=30)和600 mg/d为高剂量组(n=30);分别于治疗后1、2、4、8周评估患者的视觉模拟量表(VAS)评分、皮肤病生活质量指标(DLQI)及并发症发生情况。结果：组内比较，三组患者治疗1、2、4、8周后的VAS评分及DLQI评分均呈明显下降趋势(均P<0.05),但组间比较无明显差异(均P>0.05)。中、高剂量组患者头晕人数明显多于低剂量组，高剂量组患者嗜睡人数明显多于低剂量组(均P<0.05),三组患者带状疱疹后遗神经痛及共济失调发生情况无明显差异(均P>0.05)。结论：低剂量普瑞巴林治疗老年HZ急性疼痛患者疗效好且不良反应少，值得在临床推荐使用。
Abstract：Objective: To investigate the clinical efficacy of different doses of pregabalin in the treatment of acute pain in elderly patients with herpes zoster(HZ). Methods: Elderly patients with acute pain due to HZ(n=90) treated in Yichang Central People's Hospital from January 2021 to December 2022 were randomly divided into three groups according to the dose of pregabalin: 150 mg/d as the low-dose group(n=30), 300 mg/d as the medium-dose group(n=30), and 600 mg/d as the high-dose group(n=30). The visual analog scale(VAS), dermatology life quality index(DLQI), and occurrence of complications were evaluated at 1, 2, 4, and 8 weeks after treatment. Results: Compared within the groups, the VAS and DLQI scores of the three groups showed a significant downward trend at 1, 2, 4, and 8 weeks after treatment(all P<0.05), but there was no significant difference among the groups(all P>0.05). The number of patients with dizziness in the medium-dose and high-dose groups was significantly higher than that in the low-dose group, and the number of patients with somnolence in the high-dose group was significantly higher than that in the low-dose group(all P<0.05). There was no significant difference in the occurrence of postherpetic neuralgia and ataxia among the three groups(all P>0.05). Conclusion: Low-dose pregabalin has good efficacy and fewer adverse reactions in the treatment of acute pain in elderly patients with HZ, and it is worthy of clinical recommendation.
[1] Jeon Y H.Herpes zoster and postherpetic neuralgia:practical consideration for prevention and treatment[J].Korean J Pain,2015,28(3):177-184.
[2] Patil A,Goldust M,Wollina U.Herpes zoster:a review of clinical manifestations and management[J].Viruses,2022,14(2):192.
[3] 中华医学会皮肤性病学分会，中国康复医学会皮肤病康复专业委员会，中国中西医结合学会皮肤性病学分会，等.老年带状疱疹诊疗专家共识[J].中华皮肤科杂志，2023,56(2):97-104.
[4] 《中华医学杂志》社皮肤科慢病能力提升项目专家组，中国医师协会疼痛科医师分会，国家远程医疗与互联网医学中心皮肤科专委会.带状疱疹相关性疼痛全程管理专家共识[J].中华皮肤科杂志，2021,54(10):841-846.
[5] 陈曦，黄卓英，赵淮波，等.带状疱疹治疗及预防[J].中华医学杂志，2021,101(7):515-519.
[6] Freynhagen R,Strojek K,Griesing T,et al.Efficacy of pregabalin in neuropathic pain evaluated in a 12-week,randomised,double-blind,multicentre,placebo-controlled trial of flexible-and fixed-dose regimens[J].Pain,2005,115(3):254-263.
[7] Pavan-Langston D.Herpes zoster antivirals and pain management[J].Ophthalmology,2008,115(2 Suppl):S13-S20.
[8] 中国医师协会皮肤科医师分会带状疱疹专家共识工作组，国家皮肤与免疫疾病临床医学研究中心.中国带状疱疹诊疗专家共识(2022版)[J].中华皮肤科杂志，2022,55(12):1033-1040.
[9] 杨慧兰.带状疱疹中国专家共识解读[J].中华皮肤科杂志，2018,51(9):699-701.
[10] Goudman L,Pilitsis J G,Billet B,et al.The level of agreement between the numerical rating scale and visual analogue scale for assessing pain intensity in adults with chronic pain[J].Anaesthesia,2024,79(2):128-138.
[11] Duran S,Yürekli A.Quality of life and satisfaction with life in patients with skin diseases[J].Psychol Health Med,2023,28(10):2848-2859.
[12] Parikh R,Spence O,Giannelos N,et al.Herpes zoster recurrence:a narrative review of the literature[J].Dermatol Ther,2024.
[13] Asada H.Recent topics in the management of herpes zoster[J].J Dermatol,2023,50(3):305-310.
[14] van Oorschot D,Vroling H,Bunge E,et al.A systematic literature review of herpes zoster incidence worldwide[J].Hum Vaccin Immunother,2021,17(6):1714-1732.
[15] 刘奎玲，李晓强，孙雪华.利多卡因凝胶贴膏联合加巴喷丁治疗带状疱疹后神经痛[J].中国疼痛医学杂志，2021,27(5):386-389.
[16] 丁宗晃，魏青宇，袁春蓉.普瑞巴林联合利多卡因治疗带状疱疹后遗神经痛的临床疗效观察[J].巴楚医学，2023,6(4):75-78.
[17] 魏海明，刘金梅.A型肉毒毒素治疗带状疱疹后神经痛1例[J].医药导报，2021,40(5):634-636.
[18] 李华亮，潘平雷，陈佳慧，等.A型肉毒毒素治疗三叉神经痛和带状疱疹后神经痛的临床疗效[J].中国临床医学，2020,27(5):834-836.
[19] 黄立荣，郭佳妮，吕亚楠，等.肌筋膜内注射富含血小板血浆治疗带状疱疹后神经痛疗效观察[J].中国疼痛医学杂志，2021,27(8):631-634.
[20] 刘尧，陈立平，孙凯，等.维生素C治疗带状疱疹痛的研究进展[J].中国疼痛医学杂志，2018,24(3):161-165.
[21] 中国医师协会疼痛科医师分会，中国医师协会神经调控专业委员会.经皮穿刺短时程神经电刺激治疗带状疱疹神经痛中国专家共识[J].中国疼痛医学杂志，2021,27(11):801-805.
[22] Gónima Valero E,Mendoza W A S,Sarmiento D A,et al.Analgesic treatment approach for postherpetic neuralgia:a narrative review[J].J Pain Palliat Care Pharmacother,2023,37(2):184-193.
[23] 吴泽宇，凡艺月，杨颖.中西药治疗带状疱疹后神经痛的研究进展[J].中国医药导报，2023,20(10):59-62.
[24] Migita T.Can early administration of pregabalin reduce the incidence of postherpetic neuralgia?[J].Clin Exp Dermatol,2014,39(6):755-756.
[25] 朱谦，樊碧发，张达颖，等.周围神经病理性疼痛诊疗中国专家共识[J].中国疼痛医学杂志，2020,26(5):321-328.
[26] Schmader K.Herpes zoster[J].Ann Intern Med,2018,169(12):897.
[27] Green C B,Stratman E J.Prevent rather than treat postherpetic neuralgia by prescribing gabapentin earlier in patients with herpes zoster:comment on “incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster”[J].Arch Dermatol,2011,147(8):908.
[28] Le P,Rothberg M.Herpes zoster infection[J].BMJ,2019,364:k5095.
[29] Chen N,Li Q F,Yang J,et al.Antiviral treatment for preventing postherpetic neuralgia[J].Cochrane Database Syst Rev,2014,2014(2):CD006866.
[30] 邓宇轩，胡坚，李厚敏.不同剂量抗病毒药物对带状疱疹疗效及安全性的荟萃分析[J].中华医学杂志，2022,102(40):3192-3200.
基本信息:
中图分类号:R752.12
引用信息:
[1]丁宗晃,魏青宇,袁春蓉.不同剂量普瑞巴林治疗老年带状疱疹急性期疼痛的临床研究[J].巴楚医学,2024,7(03):66-70.
基金信息:
宜昌市医疗卫生研究项目(No:A21-2-031)
2023-10-12
2023
2024-03-11
2024-04-07
2024
1
2024-09-30
2024-09-30